3.27Open3.40Pre Close17 Volume15 Open Interest46.00Strike Price5.01KTurnover56.53%IV5.07%PremiumJan 17, 2025Expiry Date0.65Intrinsic Value100Multiplier24DDays to Expiry2.30Extrinsic Value100Contract SizeAmericanOptions Type-0.5039Delta0.0612Gamma15.64Leverage Ratio-0.0527Theta-0.0148Rho-7.88Eff Leverage0.0462Vega
PTC Therapeutics Stock Discussion
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...
New York time, with Wall Street weighing the latest economic reports ahead of next week’s Federal Reserve decision Here are some of the biggest US movers today: Gainers:
🌟 *Canopy Growth (CGC)* shares jump 20% after the cannabis company ceased funding for BioSteel Sports Nutrition on Thursday
🌟 *Nikola (NKLA)* shares gain 15% putting the electric-vehicle maker on track to extend Thursday...
No comment yet